Nexelis Marburg
Nexelis Marburg is recorded as a service provider in 9 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 9 of 9 trials · Latest update first
A Phase 3a, open-label, randomized, controlled study to evaluate the immunogenicity and safety of intramuscular administration of an investigational varicella vaccine and Priorix compared with subcutaneous administration of Varivax and Priorix, when given as a first dose to healthy children 12 to 15 months of age
Sponsor GlaxoSmithKline Biologicals
- Start (EU)
- Latest update
- Estimated end
A Phase 3b, open-label, multi-center study to assess the immune response and safety of the meningococcal group B vaccine rMenB+OMV NZ when administered to healthy participants aged 10 to 20 years old, who were primed during the first 2 years of life
Sponsor GlaxoSmithKline Biologicals
- Start (EU)
- Latest update
- Estimated end
Operational learnings available1 trial-level finding · Read insights
- A substantial global protocol amendment dated 29 August 2025 clarified eligibility criteria related to childbearing potential and contraception.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of PPV-06 Active Immunotherapy in Patients with Inflammatory Knee Osteoarthritis (KOA).
Sponsor Peptinov
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
A parallel-group prevention, Phase II, partially blinded, multi-stage study to investigate the immunogenicity and safety of Pentavalent Meningococcal ABCYW Vaccine formulations compared with licensed meningococcal vaccines when administered alone in healthy children (2 to 9 years of age) or concomitantly with routine pediatric vaccines in toddlers (12 to 15 months of age) and infants (2 months of age).
Sponsor Sanofi Pasteur Inc.
- Start (EU)
- Latest update
- Estimated end
Study 1002-041: An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Bempedoic Acid in Pediatric Patients (6 to 17 Years of Age) with Heterozygous Familial Hypercholesterolemia
Sponsor Esperion Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase II, Randomized, Partially Blinded Study to Assess the Safety, Tolerability and Immunogenicity of Meningococcal Combined ABCWY Vaccine when Administered to Healthy Infants
Sponsor GlaxoSmithKline Biologicals
- Start (EU)
- Latest update
- Estimated end
I4C-MC-JTBB: A Randomized, Controlled Phase 2 Study Evaluating LY2875358 plus Erlotinib versus Erlotinib as First-Line Treatment in Metastatic NSLC Patients with Activating EGFR Mutations Who Have Disease Control after an 8-Week Lead-In Treatment with Erlotinib
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
An Open-label, Single-arm, Multicenter Pilot Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Pegcetacoplan in Patients with Transplant-associated Thrombotic Microangiopathy (TA-TMA) After Hematopoietic Stem Cell Transplantation (HSCT)
Sponsor Swedish Orphan Biovitrum AB (publ)
- Start (EU)
- Latest update
- Estimated end
A Phase 3a, Observer-blind, Randomized, Controlled, Study to Evaluate the Immunogenicity and Safety of an Investigational Varicella Vaccine Compared with Varivax, When Given as a Second Dose to Healthy Children, 3 Months after the Administration of a First Dose at 12 to 15 Months of age
Sponsor GlaxoSmithKline Biologicals
- Start (EU)
- Not reported
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Nexelis Marburg?
The 2026-10-09 snapshot links Nexelis Marburg to 9 distinct CTIS trials. Recorded services include Laboratory services. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Nexelis Marburg?
The most frequently recorded therapeutic areas are Infectious Disease, Musculoskeletal. Recorded phases include Phase 3, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Nexelis Marburg conducted?
The linked trials record locations in 16 countries, including Spain, Denmark, Germany, Poland, Czechia. These are trial locations, not confirmed office locations or countries where Nexelis Marburg delivered services.
What can this page tell me about Nexelis Marburg's trial experience?
Browse 9 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Nexelis Marburg. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Nexelis Marburg GmbH